Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis.
Meer Rabeel ZafarSyed Farrukh MustafaTimothy W MillerTalal AlkhawlaniUmesh C SharmaPublished in: Cardio-oncology (London, England) (2020)
TAVR in the C-XRT group has similar 30-day mortality, safety, and efficacy outcomes compared to the control group; however, they have higher 1-year mortality and CHF exacerbation. Including an oncologist to the cardiology team who considers cancer stage in the decision-making process and applying additional preoperative scores such as frailty indices may refine the risk assessment for these patients. The quality of analyzed data is modest, warranting randomized trials to assess the true benefits of TAVR in these patients.
Keyphrases
- transcatheter aortic valve replacement
- end stage renal disease
- ejection fraction
- aortic stenosis
- aortic valve
- risk assessment
- radiation therapy
- chronic kidney disease
- newly diagnosed
- decision making
- prognostic factors
- heart failure
- squamous cell carcinoma
- type diabetes
- metabolic syndrome
- young adults
- risk factors
- cardiac surgery
- intensive care unit
- atrial fibrillation
- big data